Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

76.86 -1.93 (-2.45%)
Official Closing Price Updated: 7:00 PM EDT, Mar 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,886,886
Open 75.96
Bid (Size) 77.08 (1)
Ask (Size) 77.15 (2)
Prev. Close 78.79
Today's Range 75.52 - 77.29
52wk Range 73.80 - 148.15
Shares Outstanding N/A
Dividend Yield 1.33%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
This Vanguard ETF Is Crushing the Market in 2025. Should You Buy?
Via The Motley Fool
Topics ETFs

Performance

YTD
-12.2%
-12.2%
1 Month
-8.2%
-8.2%
3 Month
-13.4%
-13.4%
6 Month
-37.9%
-37.9%
1 Year
-40.3%
-40.3%

More News

Read More
Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly
Via The Motley Fool
NVO Deadline: Rosen Law Firm Urges Novo Nordisk A/S (NYSE: NVO) Stockholders to Contact the Firm for Information About Their Rights
From Rosen Law Firm
Via Business Wire
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ESSA, Cardlytics, Novo Nordisk, and Crocs and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
Is This Simple Index Fund a Millionaire Maker?
Via The Motley Fool
Is Novo Nordisk a No-Brainer Buy After It Dropped 40%?
Via The Motley Fool
Why Novo Nordisk Stock Outpaced the Market on Tuesday
Via The Motley Fool
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?
Via MarketBeat
UK Pharma Industry Trade Association Restores Wegovy/Ozempic Maker Novo Nordisk's Membership After 2 Years Of Suspension
Via Benzinga
Why Hims & Hers Stock Popped on Monday
Via The Motley Fool
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
Via The Motley Fool
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
CVS Weight Management Program Yields 15% Average Weight Loss, 26% Cost Saving Among Participants
Via Benzinga
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders
Via Benzinga
The Motley Fool's Market Volatility Toolkit
Via The Motley Fool
EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity
Via Benzinga
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Via The Motley Fool
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Via Investor's Business Daily
NVO Shareholders Have an Opportunity to Lead the Class Action Against Novo Nordisk A/S – Contact Shareholder Rights Law Firm Robbins LLP for Information
From Robbins LLP
Via GlobeNewswire
Why Hims & Hers Health Stock Just Popped
Via The Motley Fool
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 76.86
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 03/21/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.